|
|
|
|
|
|
|
|
open access
.... Clinical data in ovarian cancer show that patients with
BRCA1 and BRCA2 mutations show higher response rates to treatment with
cisplatin and other DNA-damaging agents resulting in improved outcome (Dann et al, 2012; Muggia and Safra, 2014).
Similar observations have been made in case reports of patients with
pancreatic cancer, suggesting that BRCA1 and BRCA2 mutations may
sensitise to treatment with platinum drugs (Lowery et al, 2011; Sonnenblick et al, 2011). This is supported by preclinical studies using established pancreatic cancer cell lines (van der Heijden et al, 2005),
and also by a large retrospective analysis of 71 pancreatic cancer
patients with germline BRCA1 and BRCA2 mutations, where it was reported
that patients with stage 3/4 disease who were
treated with a platinum-containing regimen had a median survival of 22
months, compared with 9 months for those who did not receive platinum (Golan et al, 2014).
There
are important unanswered questions concerning the optimum design of
platinum-containing treatment protocols for this group of patients, as
well as the role of newer agents such as inhibitors of poly-ADP-ribose
polymerase (PARP) that have shown early promise in other cancer patients
carrying germline BRCA mutations......Discussion
- Background:
- Methods:
- Results:
- Discussion:
- Materials and methods
- Results
- Discussion
- Conflict of interest
- References
- Acknowledgements
- Figures and Tables
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.